Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,092 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Maraviroc is a substrate for OATP1B1 in vitro and maraviroc plasma concentrations are influenced by SLCO1B1 521 T>C polymorphism.
Siccardi M, D'Avolio A, Nozza S, Simiele M, Baietto L, Stefani FR, Moss D, Kwan WS, Castagna A, Lazzarin A, Calcagno A, Bonora S, Back D, Di Perri G, Owen A. Siccardi M, et al. Among authors: castagna a. Pharmacogenet Genomics. 2010 Dec;20(12):759-65. doi: 10.1097/FPC.0b013e3283402efb. Pharmacogenet Genomics. 2010. PMID: 21217360 Clinical Trial.
Raltegravir, maraviroc, etravirine: an effective protease inhibitor and nucleoside reverse transcriptase inhibitor-sparing regimen for salvage therapy in HIV-infected patients with triple-class experience.
Nozza S, Galli L, Visco F, Soria A, Canducci F, Salpietro S, Gianotti N, Bigoloni A, Torre LD, Tambussi G, Lazzarin A, Castagna A. Nozza S, et al. Among authors: castagna a. AIDS. 2010 Mar 27;24(6):924-8. doi: 10.1097/QAD.0b013e3283372d76. AIDS. 2010. PMID: 20154578
Durability and safety of a novel salvage therapy in R5-tropic HIV-infected patients: maraviroc, raltegravir, etravirine.
Nozza S, Galli L, Bigoloni A, Nicola G, Pogliaghi M, Cossarini F, Salpietro S, Galli A, Della Torre L, Tambussi G, Lazzarin A, Castagna A. Nozza S, et al. Among authors: castagna a. J Acquir Immune Defic Syndr. 2011 Apr;56(4):e113-5. doi: 10.1097/QAI.0b013e31820a9ae4. J Acquir Immune Defic Syndr. 2011. PMID: 21350358 Clinical Trial. No abstract available.
Pharmacokinetics of the raltegravir/maraviroc/etravirine combination.
Calcagno A, Nozza S, Bonora S, Castagna A, Gonzalez de Requena D, D'Avolio A, Lazzarin A, Di Perri G. Calcagno A, et al. Among authors: castagna a. J Antimicrob Chemother. 2011 Aug;66(8):1932-4. doi: 10.1093/jac/dkr219. Epub 2011 Jun 4. J Antimicrob Chemother. 2011. PMID: 21642649 No abstract available.
Immune recovery and T cell subset analysis during effective treatment with maraviroc.
Cossarini F, Galli A, Galli L, Bigoloni A, Salpietro S, Vinci C, Della Torre L, Gianotti N, Spagnuolo V, Lazzarin A, Castagna A, Nozza S. Cossarini F, et al. Among authors: castagna a. J Antimicrob Chemother. 2012 Oct;67(10):2474-8. doi: 10.1093/jac/dks216. Epub 2012 Jun 7. J Antimicrob Chemother. 2012. PMID: 22678730
Risk of type 2 diabetes among HIV-infected and healthy subjects in Italy.
Galli L, Salpietro S, Pellicciotta G, Galliani A, Piatti P, Hasson H, Guffanti M, Gianotti N, Bigoloni A, Lazzarin A, Castagna A. Galli L, et al. Among authors: castagna a. Eur J Epidemiol. 2012 Aug;27(8):657-65. doi: 10.1007/s10654-012-9707-5. Epub 2012 Jun 22. Eur J Epidemiol. 2012. PMID: 22722952
1,092 results